Category Archives: Gene therapy

Pharma Report Predicts Trillion Dollar Global Industry by 2020

By Colin McMahon. EvalutePharma’s seventh edition of its World Preview documents that worldwide prescription drug sales forecast will exceed the one trillion dollar mark by 2020. The company bases this estimate on the growing compound annual growth rate (CAGR) that the pharmaceutical industry is currently enjoying. It predicts that CAGR will continue to grow through […]
Also posted in FDA, Global, Guest Blog, R&D, Strategy | Tagged , , | Leave a comment

UK Strengthens Drive to Tackle Dementia

The UK government pledged late last year that it would double funding for dementia research by 2025 (from £66m [US$112m] in 2015 to £122m [US$207m]), but today Prime Minister David Cameron spoke on the subject again in light of expert warnings that little progress is being made. At the first legacy event of the G8 […]
Also posted in Europe, Events, Global, healthcare | Tagged , , , | Leave a comment

Increase of Biosimilars Will Have “Negative Impact”

A new report from GlobalData states that the increase of biosimilars will have a negative impact on the biologics market after 2019. The report cites patent expirations of branded biologics and regulatory clarification as reasons for the prediction that biosimilars will capture the market share after 2019.
Also posted in Biotech, Events, Global | Tagged , , | Leave a comment

EU Blocks Further Limits on Human Embryo Research, Backlash Hits

By Peter O’ Donnell, Applied Clinical Trials. A European bid to impose additional limits on research involving human embryos has been defeated. European Union officials decided last week (May 28) that there was no need to introduce new legislation in this area, since it is already regulated, and the existing policy received endorsement from the […]
Also posted in Europe, Global, Guest Blog, Regulatory | Tagged , , | Leave a comment

Eight Ingredients for a Successful Oncology Drug Development Recipe

by Matthew Cook and Sebastien Morisot In light of the risks and challenges inherent in the development of oncologics, some biopharma companies are beginning to question whether oncology remains an attractive therapeutic area in which to invest limited research, development, and commercialization resources.
Also posted in Agency Insight, Biotech, Europe, FDA, Guest Blog, leadership, Market Access, Orphan Drugs, pricing, R&D, Regulatory, Sales | Tagged , , | Leave a comment
  • Categories

  • Meta